MCID: VLV010
MIFTS: 42

Vulvovaginitis

Categories: Reproductive diseases

Aliases & Classifications for Vulvovaginitis

MalaCards integrated aliases for Vulvovaginitis:

Name: Vulvovaginitis 12 74 54 44 15 17 71
Vulvo-Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2273
MeSH 44 D014848
NCIt 50 C35131
SNOMED-CT 67 155981006
ICD10 32 N76.0
UMLS 71 C0042998

Summaries for Vulvovaginitis

Disease Ontology : 12 A female reproductive system disease that is characterized by inflammation of the vagina and vulva.

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to vaginitis and vulvitis. An important gene associated with Vulvovaginitis is HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Allograft rejection. The drugs Lidocaine and Tinidazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and kidney.

Wikipedia : 74 Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include... more...

Related Diseases for Vulvovaginitis

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 vaginitis 32.1 IL10 CXCL8 CCL5
2 vulvitis 31.9 SLC5A4 SLC5A2
3 vaginal discharge 31.2 IL10 CXCL8
4 trichomoniasis 30.9 IL10 CXCL8
5 chlamydia 30.7 IL10 HSPD1 CXCL8
6 cervicitis 30.5 IL10 HSPD1 CXCL8
7 urethritis 30.3 IL10 HSPD1 CXCL8
8 acute cervicitis 30.2 IL10 CXCL8
9 allergic rhinitis 30.2 IL10 CXCL8 CCL5 CCL11
10 dermatitis 30.2 IL10 CXCL8 CCL5 CCL11
11 rhinitis 30.1 IL10 CXCL8 CCL5 CCL11
12 bacterial infectious disease 30.0 IL10 HSPD1 CXCL8
13 vaginal disease 30.0 IL10 CXCL8 CCL5
14 pyelonephritis 29.9 IL10 CXCL8 CCL5
15 conjunctivitis 29.9 IL10 CXCL8 CCL11
16 dermatitis herpetiformis 29.9 IL10 CXCL8 CCL11
17 keratoconjunctivitis 29.9 CXCL8 CCL5 CCL11
18 toxic shock syndrome 29.9 IL10 HSPD1 CXCL8
19 skin disease 29.7 IL10 HSPA4 DPP4 CXCL8 CCL11
20 dermatitis, atopic 29.7 IL10 CXCL8 CCL5 CCL11
21 type 1 diabetes mellitus 29.6 IL10 HSPD1 CXCL8 CCL11
22 balanoposthitis 29.6 SLC5A4 SLC5A2 SLC5A1 DPP4
23 balanitis 29.6 SLC5A4 SLC5A2 SLC5A1 DPP4
24 acute cystitis 29.0 SLC5A4 SLC5A2 SLC5A1 IL10 DPP4 CXCL8
25 vulvovaginal candidiasis 11.4
26 vulvovaginitis, allergic seminal 11.0
27 vulvar disease 10.9
28 candidiasis 10.6
29 bacterial vaginosis 10.4
30 candida glabrata 10.4
31 acute transverse myelitis 10.4 IL10 CXCL8
32 acute gonococcal cervicitis 10.3 IL10 CXCL8
33 neurosyphilis 10.3 IL10 CXCL8
34 mycobacterium fortuitum 10.3 HSPD1 CXCL8
35 spotted fever rickettsiosis 10.3 IL10 CCL5
36 chromium allergic contact dermatitis 10.3 IL10 CCL5
37 chronic graft versus host disease 10.3 IL10 CCL5
38 bacterial conjunctivitis 10.3 IL10 CXCL8
39 enterocolitis 10.3 IL10 CXCL8
40 progressive myoclonus epilepsy 8 10.3 IL10 CXCL8
41 orofacial granulomatosis 10.3 IL10 CCL5
42 primary peritoneal carcinoma 10.3 IL10 CXCL8
43 basidiobolomycosis 10.3 IL10 HSPD1
44 mansonelliasis 10.3 IL10 CXCL8
45 loiasis 10.3 IL10 CCL11
46 tungiasis 10.3 IL10 CXCL8
47 low grade glioma 10.3 HSPD1 HSPA4
48 mucocutaneous leishmaniasis 10.3 IL10 HSPA4
49 trichinosis 10.3 IL10 CCL11
50 haemophilus influenzae 10.3

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis

Symptoms & Phenotypes for Vulvovaginitis

Drugs & Therapeutics for Vulvovaginitis

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
3
Dequalinium Approved, Investigational Phase 4 6707-58-0
4
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
5
Estrone Approved Phase 4 53-16-7 5870
6 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
7 Hypoglycemic Agents Phase 4
8 Sodium-Glucose Transporter 2 Inhibitors Phase 4
9 Anti-Infective Agents, Local Phase 4
10 Cytochrome P-450 CYP3A Inhibitors Phase 4
11 Acidophilus Phase 4
12 Pycnogenols Phase 4
13 Estrogens Phase 4
14 Liver Extracts Phase 4
15 Estrogens, Conjugated (USP) Phase 4
16 Estrogen Receptor Modulators Phase 4
17 Estropipate Phase 4 7280-37-7
18 Estrogens, Esterified (USP) Phase 4
19
Butoconazole Approved Phase 3 64872-76-0, 64872-77-1 47472
20
tannic acid Approved Phase 3 1401-55-4
21
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
22
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
23
Polyestradiol phosphate Approved Phase 3 28014-46-2
24
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
25
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
26 Hormone Antagonists Phase 3
27 Estradiol 17 beta-cypionate Phase 3
28 Estradiol 3-benzoate Phase 3
29 Estrogens, conjugated synthetic A Phase 3
30 Estrogens, conjugated synthetic B Phase 3
31 Antifungal Agents Phase 2, Phase 3
32 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
33 Anti-Infective Agents Phase 2, Phase 3
34
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
35
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
36
Petrolatum Approved, Investigational Phase 2 8009-03-8
37
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
38
Mineral oil Approved, Vet_approved Phase 2 8042-47-5
39
Glycerol Approved, Investigational Phase 2 56-81-5 753
40
Loperamide Approved Phase 2 53179-11-6 3955
41
Calcium polycarbophil Approved Phase 2 126040-58-2
42
Rezafungin Investigational Phase 2 1396640-59-7
43 Albaconazole Investigational Phase 2 187949-02-6
44 Vaccines Phase 1, Phase 2
45 Tea Phase 2
46 Protein Kinase Inhibitors Phase 2
47 Protective Agents Phase 2
48 Cathartics Phase 2
49 Gastrointestinal Agents Phase 2
50 Dermatologic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Completed NCT04193566 Phase 4 Forxiga
2 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
3 Open-Label Pilot Prospective Vulvoscopy Photography Study of Visible Changes in the Vulva, Vestibule, Vagina Pre/Post 20 Weeks of Daily Administration 60 Mg Ospemifene in Post-Menopausal Women With Dyspareunia From Vulvar Vaginal Atrophy Completed NCT02784613 Phase 4 Ospemifene
4 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
6 Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms of Vulvovaginal Dryness in a Parallel Group Design Completed NCT03044652 Phase 4 Estriol Cream 0.1%
7 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
8 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
9 Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders Recruiting NCT04677491 Phase 4 Ospemifene 60 mg
10 A Prospective, Case-controlled Randomized Study of Human Reproductive Tract Active Lactobacillus in Adjuvant Treatment of Recurrent Vulvovaginal Candidiasis. Recruiting NCT04699240 Phase 4 clotrimazole vaginal tablets;Clotrimazole vaginal tablets+ Lactobacillus
11 A Randomized Controlled Trial to Compare the Efficacy of a Medical Grade Honey Formulation (L-Mesitran®) and Fluconazol (Diflucan®) for the Treatment of Recurrent Vulvovaginal Candidiasis Not yet recruiting NCT04626258 Phase 4 Fluconazole
12 Ospemifene Versus Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction Terminated NCT03018106 Phase 4 Ospemifene;Vaginal conjugated estrogens
13 A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy Unknown status NCT03782480 Phase 3 Intrarosa;Placebos
14 A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause Completed NCT02638337 Phase 3 Ospemifene;Placebo
15 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Completed NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
16 Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories. Completed NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
17 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
18 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Completed NCT03987620 Phase 3 Ibrexafungerp;Placebo
19 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03734991 Phase 3 Ibrexafungerp;Placebo
20 A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women With Dyspareunia Completed NCT01845649 Phase 3 Estradiol Vaginal Gel;Vehicle
21 A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women Completed NCT01400776 Phase 3 WC3011 Vaginal Gel;Vehicle
22 A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women Completed NCT01816139 Phase 3 WC3011;Vehicle
23 A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis. Completed NCT01806623 Phase 3 Fluconazole
24 Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream Completed NCT04232813 Phase 3 Estradiol 10 MCG Vaginal Tablet [VAGIFEM];Promestriene Vaginal
25 A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women Completed NCT01455597 Phase 3 Estradiol Vaginal Gel
26 Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy Completed NCT02419729 Phase 3 Estrogen;Placebo of Estrogen
27 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
28 A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
29 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Completed NCT02253173 Phase 3 Estradiol;Placebo
30 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks of Treatment With DR-2041(Synthetic Conjugated Estrogens, A) Vaginal Cream vs. Placebo Vaginal Cream on Vulvovaginal Atrophy in Healthy Postmenopausal Women Completed NCT00361569 Phase 3 DR-2041a;DR-2041b
31 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
32 Phase III, Multicenter, Double-Blind Study of the Safety and Efficacy of Bio-E-Gel (Topical Estradiol Gel) Versus Placebo for Treatment of Vasomotor Symptoms and Vulvovaginal Atrophy in Postmenopausal Females Completed NCT00391417 Phase 3 estradiol gel
33 Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management Completed NCT00353561 Phase 3 Boric;Fluconazole
34 A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, B (Enjuvia) 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women Completed NCT00196378 Phase 3 Synthetic Conjugated estrogens, B
35 Phase IIb/III Parallel-arm, Random., Active-controlled, Double-blind, Double-dummy, Multicenter, Non-inferiority Study in Patients With RVVC to Compare Efficacy, Safety and Tolerability of Topically Administered ProF-001 to Oral Fluconazole Recruiting NCT04734405 Phase 2, Phase 3 Prof-001;Fluconazole 150 mg;Placebo cream;Placebo capsule
36 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Active, not recruiting NCT03562156 Phase 3 VT-1161;Placebo
38 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Active, not recruiting NCT03561701 Phase 3 VT-1161;Placebo
39 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
40 Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study) Withdrawn NCT03740945 Phase 3 Placebo;Prasterone (DHEA)
41 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Unknown status NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
42 A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
43 A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
44 Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
45 A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
46 A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vulvovaginal Atrophy Completed NCT04629885 Phase 2 Oxytocin 400 IU vaginal gel;Placebo
47 A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
48 A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate Safety and Efficacy of Three Doses of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy Completed NCT02670785 Phase 2 Estradiol Vaginal Capsule (EVC);Placebo
49 Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
50 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Genetic Tests for Vulvovaginitis

Anatomical Context for Vulvovaginitis

MalaCards organs/tissues related to Vulvovaginitis:

40
Skin, Liver, Kidney, Bone Marrow, Breast, Lymph Node, Placenta

Publications for Vulvovaginitis

Articles related to Vulvovaginitis:

(show top 50) (show all 1193)
# Title Authors PMID Year
1
Detection of the human 70-kD and 60-kD heat shock proteins in the vagina: relation to microbial flora, vaginal pH, and method of contraception. 54 61
10231004 1999
2
Rapid and simple colorimetric loop-mediated isothermal amplification (LAMP) assay for the detection of Bovine alphaherpesvirus 1. 61
33309756 2021
3
Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). 61
33529414 2021
4
Clinical Predictive Value of the Urine Leukocyte Esterase Test Positivity in the Childhood. 61
33548092 2021
5
Potential role of the skin and gut microbiota in premenarchal vulvar lichen sclerosus: A pilot case-control study. 61
33444404 2021
6
Prevalence and Antimicrobial Susceptibility Profiles of Microorganisms Associated with Lower Reproductive Tract Infections in Women from Southern Poland-Retrospective Laboratory-Based Study. 61
33466345 2021
7
Characteristics of the vaginal microbiomes in prepubertal girls with and without vulvovaginitis. 61
33452946 2021
8
Investigating natural antibiofilm components: a new therapeutic perspective against candidal vulvovaginitis. 61
33549963 2021
9
FbD directed fabrication and investigation of luliconazole based SLN gel for the amelioration of candidal vulvovaginitis: a 2 T (thermosensitive & transvaginal) approach. 61
33424312 2021
10
Identifying a knowledge deficit among paediatric and GP trainees in paediatric and adolescent gynaecology in an Irish hospital: a pilot study. 61
33515700 2021
11
Treatment of vulvovaginitis. 61
33363301 2020
12
Acute urinary retention in children. 61
32900634 2020
13
Novel antigenic proteins of Mycoplasma agalactiae as potential vaccine and serodiagnostic candidates. 61
33099078 2020
14
Comparison of Short-Duration and Chronic Premenarchal Vulvar Complaints. 61
33246095 2020
15
Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes. 61
33016178 2020
16
Laboratorial Aspects of Cytolytic Vaginosis and Vulvovaginal Candidiasis as a Key for Accurate Diagnosis: A Pilot Study. 61
33129219 2020
17
An Overview of Seminal Plasma Hypersensitivity and Approach to Treatment. 61
33039013 2020
18
Treating vaginitis with probiotics in non-pregnant females: A systematic review and meta-analysis. 61
32855726 2020
19
Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness. 61
32997581 2020
20
Candida africana vulvovaginitis: Prevalence and geographical distribution. 61
32317216 2020
21
Prepubertal Vulvovaginitis. 61
32282354 2020
22
Detection of COVID-19 in a Vulvar Lesion. 61
32615620 2020
23
The use of 3 selected lactobacillary strains in vaginal probiotic gel for the treatment of acute Candida vaginitis: a proof-of-concept study. 61
32356027 2020
24
Evaluation of vulvovaginitis in the adolescent patient. 61
32778468 2020
25
Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report. 61
32447330 2020
26
Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. 61
31970513 2020
27
Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC). 61
32253071 2020
28
Are probiotics an appropriate treatment option for all women? 61
32363913 2020
29
Vulvovaginitis and dog allergy. 61
32089402 2020
30
Prepubertal and Adolescent Vulvovaginitis: What to Do When a Girl Reports Vaginal Discharge. 61
32275761 2020
31
Prepubertal Vaginal Bleeding: An Inpatient Series from a Single Center in Fujian China. 61
31765797 2020
32
Applying the Host-Microbe Damage Response Framework to Candida Pathogenesis: Current and Prospective Strategies to Reduce Damage. 61
32168864 2020
33
Vaginal discharge caused by lymphatic malformation identified by lymphoscintigraphy combined with T2-weighted magnetic resonance imaging. 61
32025595 2020
34
In vitro anticandidal potency of Syzygium aromaticum (clove) extracts against vaginal candidiasis. 61
32020877 2020
35
Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon. 61
31931738 2020
36
Herpesvirus diseases of domestic animals and game species in the Slovak Republic. 61
33112639 2020
37
The role of maternal infection in preterm birth: evidence from the Brazilian Multicentre Study on Preterm Birth (EMIP). 61
32215453 2020
38
In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis. 61
31901238 2020
39
Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates. 61
32941438 2020
40
[Occult foreign body: A rare cause of recurrent vulvovaginitis]. 61
30482451 2020
41
Evaluation of Vulvovaginitis and Hygiene Habits of Women Attended in Primary Health Care Units of the Family. 61
32099484 2020
42
Clinical and Microbiological Findings of Vulvovaginitis in Prepubertal Girls. 61
31445141 2019
43
Parental experiences of their child's vulvovaginitis: a qualitative interview study. 61
31451410 2019
44
Alleviation of vulvovaginitis symptoms: can probiotics lead the treatment plan? 61
31965832 2019
45
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. 61
30945022 2019
46
Streptococcal toxic shock syndrome following group A streptococcal vulvovaginitis in a breastfeeding woman. 61
31151810 2019
47
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. 61
31707496 2019
48
Estimated burden of fungal infections in Sweden. 61
31376228 2019
49
Myofascial Release for Vulvar Pain and Pubic Shear After a Straddle Injury in a 3-Year-Old Girl. 61
31657831 2019
50
Immunological Methods for Treatment of Vulvovaginal Infections in the Preconception Period. 61
32025255 2019

Variations for Vulvovaginitis

Expression for Vulvovaginitis

Search GEO for disease gene expression data for Vulvovaginitis.

Pathways for Vulvovaginitis

GO Terms for Vulvovaginitis

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 chemotaxis GO:0006935 9.75 CXCL8 CCL5 CCL11
2 cellular response to tumor necrosis factor GO:0071356 9.72 CXCL8 CCL5 CCL11
3 cytokine-mediated signaling pathway GO:0019221 9.71 IL10 CXCL8 CCL5 CCL11
4 sodium ion transport GO:0006814 9.69 SLC5A4 SLC5A2 SLC5A1
5 glucose transmembrane transport GO:1904659 9.57 SLC5A4 SLC5A1
6 chaperone-mediated protein complex assembly GO:0051131 9.56 HSPD1 HSPA4
7 positive regulation of macrophage activation GO:0043032 9.54 IL10 HSPD1
8 cellular response to interleukin-1 GO:0071347 9.54 CXCL8 CCL5 CCL11
9 sodium ion import across plasma membrane GO:0098719 9.52 SLC5A2 SLC5A1
10 neutrophil chemotaxis GO:0030593 9.5 CXCL8 CCL5 CCL11
11 eosinophil chemotaxis GO:0048245 9.49 CCL5 CCL11
12 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.48 CXCL8 CCL5
13 neutrophil activation GO:0042119 9.46 CXCL8 CCL5
14 response to molecule of bacterial origin GO:0002237 9.43 IL10 CXCL8
15 chemokine-mediated signaling pathway GO:0070098 9.43 CXCL8 CCL5 CCL11
16 glucose import across plasma membrane GO:0098708 9.16 SLC5A2 SLC5A1
17 positive regulation of cellular biosynthetic process GO:0031328 8.96 CXCL8 CCL5
18 alpha-glucoside transport GO:0000017 8.62 SLC5A2 SLC5A1

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 IL10 CXCL8 CCL5 CCL11
2 chemokine activity GO:0008009 9.33 CXCL8 CCL5 CCL11
3 D-glucose transmembrane transporter activity GO:0055056 9.26 SLC5A2 SLC5A1
4 alpha-glucoside transmembrane transporter activity GO:0015151 8.96 SLC5A2 SLC5A1
5 glucose:sodium symporter activity GO:0005412 8.8 SLC5A4 SLC5A2 SLC5A1

Sources for Vulvovaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....